Abstract
Hypertension is a major contributor to vascular morbidity and mortality. Endocrine hypertension (EH) refers to secondary hypertension caused by specific endocrine abnormalities. The significance of EH is that the identification of the underlying disorder and its management may lead to partial or complete normalization of blood pressure. When EH is suspected thorough investigation with biochemical and imaging testing are necessary to establish or exclude mineralocorticoid, catecholamine, glucocorticoid, thyroid, parathyroid or growth hormone disorders as well as rare hereditary syndromes. In addition, it is important to differentiate benign from malignant tumors. The present review provides an update on the pathophysiology and clinical presentation of EH. We also discuss the diagnostic work-ups and therapeutic strategies.
Keywords: Endocrine hypertension, primary aldosteronism, pheochromocytoma, Cushing's syndrome
Current Vascular Pharmacology
Title: Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity
Volume: 8 Issue: 5
Author(s): Panagiotis Anagnostis, Asterios Karagiannis, Konstantinos Tziomalos, Vasilios G. Athyros, Marina Kita and Dimitri P. Mikhailidis
Affiliation:
Keywords: Endocrine hypertension, primary aldosteronism, pheochromocytoma, Cushing's syndrome
Abstract: Hypertension is a major contributor to vascular morbidity and mortality. Endocrine hypertension (EH) refers to secondary hypertension caused by specific endocrine abnormalities. The significance of EH is that the identification of the underlying disorder and its management may lead to partial or complete normalization of blood pressure. When EH is suspected thorough investigation with biochemical and imaging testing are necessary to establish or exclude mineralocorticoid, catecholamine, glucocorticoid, thyroid, parathyroid or growth hormone disorders as well as rare hereditary syndromes. In addition, it is important to differentiate benign from malignant tumors. The present review provides an update on the pathophysiology and clinical presentation of EH. We also discuss the diagnostic work-ups and therapeutic strategies.
Export Options
About this article
Cite this article as:
Anagnostis Panagiotis, Karagiannis Asterios, Tziomalos Konstantinos, G. Athyros Vasilios, Kita Marina and P. Mikhailidis Dimitri, Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity, Current Vascular Pharmacology 2010; 8 (5) . https://dx.doi.org/10.2174/157016110792006996
DOI https://dx.doi.org/10.2174/157016110792006996 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension in Patients with Severe Aortic Stenosis: Emphasis on Antihypertensive Treatment and the Risk of Syncope
Current Hypertension Reviews Cholinesterase Inhibitors Slow Decline in Executive Functions, Rather than Memory, in Alzheimers Disease: A 1-Year Observational Study in the Sunnybrook Dementia Cohort
Current Alzheimer Research Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Effects of a Hypocaloric Diet on Obesity Biomarkers: Prevention of Low-Grade Inflammation since Childhood
Current Pharmaceutical Design Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Prediction and Targeting of Interaction Interfaces in G-protein Coupled Receptor Oligomers
Current Topics in Medicinal Chemistry Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Synthesis and Antithrombotic Activity Study of Some New Thienopyridine Derivatives
Letters in Organic Chemistry Inflammation, Adiponectin, Obesity and Cardiovascular Risk
Current Medicinal Chemistry Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology Definitions of Metabolic Syndrome: Where are We Now?
Current Vascular Pharmacology Antiplatelet Therapies: Aspirin at the Heart of New Directions
Cardiovascular & Hematological Disorders-Drug Targets Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention
Current Vascular Pharmacology New Biotechnological Methods to Reduce Oxidative Stress in the Cardiovascular System: Focusing on the Bach1/Heme Oxygenase-1 Pathway
Current Pharmaceutical Biotechnology Editorial: (Thematic Issue: Vascular Pathophysiology of Alzheimer`s Disease)
Current Alzheimer Research Recent Synthetic Strategies for Monocyclic Azole Nucleus and Its Role in Drug Discovery and Development
Current Organic Synthesis Sedation in PACU: Indications, Monitoring, Complications
Current Drug Targets Exercise and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets The Use of Unsaturated Fatty Acids in Liposomal Form to Get Bread Enriched with ω-3 Fatty Acids
Current Nutrition & Food Science Central Blood Pressure and Prediction of Cardiovascular Events
Current Hypertension Reviews